Oral Anticoagulant Therapy

Managing oral anticoagulant therapy.

2001;119;22S-38S Chest Leon Poller, Alan Jacobson, Daniel Deykin and David Matchar Jack Ansell, Jack Hirsh, James Dalen, Henry Bussey, David Anderson, Managing Oral Anticoagulant Therapy l.html http://chestjournal.chestpubs.org/content/119/1_suppl/22S.ful and services can be found online on the World Wide Web at: The online version of this article, along with updated information ISSN:0012-3692 ...

Oral Anticoagulant Therapy

on laboratory and clinical monitoring and on reversal strategies. More recently, new oral anticoagulant drugs, namely the direct thrombin inhibitor dabigatran etexilate and the direct factor Xa inhibitor rivaroxaban, have been approved for clinical use in several countries. A growing body of laboratory and clinical data is becoming available to better understand the mechanisms of action and the...

Pharmacogenetics of oral anticoagulant therapy

Pharmacogenetics of oral anticoagulant therapy

Introduction In the last 70 years the antagonists of vitamin K (AVK) were the only therapeutic solution for oral anticoagulation in primary and secondary prophylaxis of arterial and venous thrombosis. The utility of AVK was demonstrated in many situations and presently they are taken by millions patients in the entire world. Many clinical and lab studies contributed to understanding of AVKs’ ph...

Patient education and oral anticoagulant therapy.

BACKGROUND AND OBJECTIVES The stability of oral anticoagulant therapy is affected by an irregular intake of vegetables, interactions with other drugs, intercurrent disease, and compliance. With the aim of investigating whether educating patients could affect anticoagulation stability, we prepared a questionnaire on the basis of some fundamental information given by us to our patients during the...